scorecardresearchCaplin Point Laboratories Share Price Live NSE, BSE, Today - Caplin Point
Mintgenie
Asian Paints2,931.203.70 (0.13%)
Axis Bank1,145.003.95 (0.35%)
Bajaj Finance6,861.05-71.75 (-1.03%)
Bajaj Finserv1,611.55-15.55 (-0.96%)
Bharti Airtel1,284.507.75 (0.61%)
HCL Technologies1,358.0510.25 (0.76%)
HDFC Bank1,522.804.15 (0.27%)
Hindustan Unilever2,255.3539.85 (1.80%)
ICICI Bank1,148.806.80 (0.60%)
ITC434.60-1.65 (-0.38%)
Indusind Bank1,498.3515.65 (1.06%)
Infosys1,425.809.35 (0.66%)
Kotak Mahindra Bank1,624.7577.50 (5.01%)
Larsen & Toubro3,462.10-37.00 (-1.06%)
Mahindra & Mahindra2,225.1032.15 (1.47%)
Maruti Suzuki India12,435.25-55.90 (-0.45%)
NTPC356.65-8.45 (-2.31%)
Nestle India2,458.002.40 (0.10%)
Power Grid Corporation Of India306.90-3.80 (-1.22%)
Reliance Industries2,839.00-29.50 (-1.03%)
State Bank Of India807.75-23.80 (-2.86%)
Sun Pharmaceutical Industries1,529.5521.15 (1.40%)
Tata Consultancy Services3,921.0081.65 (2.13%)
Tata Motors1,015.802.00 (0.20%)
Tata Steel167.601.15 (0.69%)
Tech Mahindra1,263.5513.90 (1.11%)
Titan Company3,281.65-253.75 (-7.18%)
Ultratech Cement9,779.80-36.95 (-0.38%)
Wipro458.251.40 (0.31%)

Caplin Point Laboratories

BSE: 524742 | NSE: CAPLIPOINT | ISIN: INE475E01026 | SECTOR: Biotechnology & Drugs

₹1,330.00 31.20 (2.4%)

06 May 2024, 09:59 (IST)

  • Open

    1,300.00

  • High

    1,330.00

  • Low

    1,277.85

  • Prev Close

    1,298.80

  • P/E

    -

  • Median P/E

    -

  • P/B

    -

  • Median P/B

    -

  • Market Cap

    101.00B

  • Volume

    19.29K

  • Vol. (20 day Avg.)

    0

  • PEG

    -

  • Div.Yield

    -

  • Bid

    -

  • Ask

    1,311.00
View all metrics

Company Description

  • Biotechnology & Drugs

  • BSE

    524742

  • NSE

    CAPLIPOINT

  • ISIN

    INE475E01026

Caplin Point Laboratories Limited is an India-based pharmaceutical company. The Company is engaged in producing, developing, and marketing a range of generic formulations and branded products and exporting to overseas markets. Its products include tablets, dry syrups (bottles), soft gels, capsules, suppositories, liquid syrups (bottles), liquid injectables in ampoules and vials, lyophilized vials, prefilled syringes (PFS), emulsion injection in ampoules and vials, ophthalmic droppers, pre-mix bags, topicals and sachets (liquids and powders). It also manufactures a range of ointments, creams, gels and lotions. Its principal research and development facilities are in Tamil Nadu, India. Its principal manufacturing facility is in Puducherry, India. It has presence in Latin America (LATAM), Southern Africa and Francophone Africa along with a presence in United States of America and European region. The Company’s subsidiaries include Caplin Point Far East Limited and Caplin Steriles Limited.

Company Officers

  • D. Muralidharan

    Chief Financial Officer

  • G. Venkatram

    Compliance Officer, General Counsel, Company Secretary

  • Sridhar Ganesan

    Managing Director, Executive Director